Brenda J. Weigel

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 27 papers. Top paper: “Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial”.

Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30023-1

N/A

5.0DataRank · unranked

337 citations

Elizabeth Fox, Melinda S. Merchant, Joel M. Reid, Rachel A. Kudgus, Xiaowei Liu +6 more

Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children’s Oncology Group

Cancer Discovery(2024)10.1158/2159-8290.cd-23-1376

N/A

0.590DataRank · unranked

16 citations

Alex G. Lee, Steven P. Angus, Christopher Davis, Donald A. Barkauskas, David Hall +10 more

A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase‐Clinical Trial Network (PEP‐CTN)

Pediatric Blood & Cancer(2021)10.1002/pbc.28892

N/A

0.550DataRank · unranked

38 citations

Bill H. Chang, Joel M. Reid, Xiaowei Liu, Charles G. Minard, Jane B. Trepel +4 more

Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma

Cancer(2023)10.1002/cncr.34786

N/A

0.529DataRank · unranked

33 citations

Heba Ijaz, Lea F. Surrey, Mariarita Santi, Xiaowei Liu, Charles G. Minard +6 more

Racial and Ethnic Differences in Sarcoma Incidence Are Independent of Census-Tract Socioeconomic Status

Cancer Epidemiology Biomarkers & Prevention(2020)10.1158/1055-9965.epi-20-0520

N/A

0.470DataRank · unranked

22 citations

Brenda J. Weigel, Paari Murugan, Lin Zhang, Jenny N. Poynter, Logan G. Spector +1 more

Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615)

European Journal of Cancer(2024)10.1016/j.ejca.2024.114241

N/A

0.416DataRank · unranked

15 citations

Joel M. Reid, Charles G. Minard, Sarah E. Woodfield, Kristina Z. Denic, Emasenyie Isikwei +7 more

Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G

The Oncologist(2024)10.1093/oncolo/oyae119

N/A

0.363DataRank · unranked

7 citations

AeRang Kim, P. Mickey Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +17 more

A phase 1/2 study of bay 18953444 (Elimusertib) in pediatric patients with relapsed or refractory solid tumors: Initial report of the phase 1 results of PEPN2112.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e15131

N/A

0.345DataRank · unranked

9 citations

Julia Glade Bender, Charles G. Minard, Xiaowei Liu, Kristina Z. Denic, Joel M. Reid +8 more

Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10019

N/A

0.208DataRank · unranked

3 citations

Joel M. Reid, Charles G. Minard, Emasenyie Isikwei, Xiaowei Liu, Stacey L. Berg +4 more

Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712

Pediatric Blood & Cancer(2023)10.1002/pbc.30672

N/A

0.208DataRank · unranked

3 citations

Xiaowei Liu, Charles G. Minard, Emasenyie Isikwei, Joel M. Reid, Terzah M. Horton +4 more

Data from A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412

(2023)10.1158/1078-0432.c.6532749

N/A

0DataRank · unranked

0 citations

Elizabeth Fox, Emasenyie Isikwei, Joel M. Reid, Xiaowei Liu, Charles G. Minard +5 more

Data from A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412

(2023)10.1158/1078-0432.c.6532749.v1

N/A

0DataRank · unranked

0 citations

Elizabeth Fox, Emasenyie Isikwei, Joel M. Reid, Xiaowei Liu, Charles G. Minard +5 more

Roadmap for the next generation of Children’s Oncology Group rhabdomyosarcoma trials

Cancer(2024)10.1002/cncr.35457

N/A

0DataRank · unranked

4 citations

Jamie M. Aye, Jacquelyn Crane, Sapna Oberoi, Frank M. Balis, Smita Bhatia +18 more

Toxicity Profile of eBAT, a Bispecific Ligand-Targeted Toxin Directed to EGFR and uPAR, in Mice and a Clinical Dog Model

Toxins(2024)10.3390/toxins16090376

N/A

0DataRank · unranked

1 citations

Jill T. Schappa, Ashley J. Schulte, Haeree P. Lang, Ellen Marie Kuerbitz, Sarah Roberts +20 more

Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug Administration

European Journal of Cancer(2025)10.1016/j.ejca.2025.115629

N/A

0DataRank · unranked

4 citations

Susan Chi, Theodore W Laetscht, Lynley V. Marshall, Elizabeth A. Raetz, Rani E. George +34 more

Remodeling the sarcoma microenvironment by simultaneous targeting of urokinase-type plasminogen activator receptors and epidermal growth factor receptors to promote antitumor activity

Journal of Pharmacology and Experimental Therapeutics(2025)10.1016/j.jpet.2025.103674

N/A

0DataRank · unranked

1 citations

Mitzi Lewellen, Wilaiwan Durose, Erin E. Nolan, Leyla Taghizadeh, D.A. Todhunter +18 more

Prioritization of novel agents for further investigation in pediatric non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children’s Oncology Group

European Journal of Cancer(2025)10.1016/j.ejca.2025.115600

N/A

0DataRank · unranked

1 citations

David P. Douglass, Sapna Oberoi, Natalie B. Collins, Ajay Gupta, Jonathan Metts +17 more

5‐fluoro‐deoxyglucose PET/CT response after neoadjuvant chemotherapy predicts long‐term outcomes in soft tissue sarcomas: Results from a prospective trial

Cancer(2025)10.1002/cncr.70129

N/A

0DataRank · unranked

0 citations

Andrea P. Espejo Freire, J. Carlos Manivel, Jerry Froelich, Brenda J. Weigel, Denis R. Clohisy +6 more

A phase II study of larotrectinib for children with newly diagnosed solid tumors and relapsed acute leukemias harboring TRK fusions: Children’s Oncology Group study ADVL1823.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps10560

N/A

0DataRank · unranked

2 citations

Kathleen Ludwig, Donald A. Barkauskas, Steven G. DuBois, Joan Ronan, Erin R. Rudzinski +10 more

First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children’s Oncology Group Phase 1/Pilot Consortium

UNC Libraries(2020)10.17615/dawp-6r12

N/A

0DataRank · unranked

0 citations

Yaël P. Mossé, Patrick A. Thompson, Frank M. Balis, Elizabeth Fox, Susan M. Blaney +2 more

Phase 2 trial of cabozantinib in children and young adults with refractory sarcomas, Wilms tumor, and rare tumors: Children's Oncology Group Study (ADVL1622).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10010

N/A

0DataRank · unranked

26 citations

Brigitte C. Widemann, Donald A. Barkauskas, David Hall, Joel M. Reid, Stephan D. Voss +4 more

Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10018

N/A

0DataRank · unranked

0 citations

Xiaowei Liu, Charles G. Minard, Sarah Menig, Joel M. Reid, Emasenyie Isikwei +6 more

A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2164

N/A

0DataRank · unranked

72 citations

Elizabeth Fox, Emasenyie Isikwei, Joel M. Reid, Xiaowei Liu, Charles G. Minard +5 more

Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children’s Oncology Group phase I consortium study

Neuro-Oncology Advances(2022)10.1093/noajnl/vdac073

N/A

0DataRank · unranked

16 citations

Tabitha Cooney, Xiaodong Yang, Sharmistha Pal, Ralph P. Ermoian, Amar Gajjar +9 more

Rhabdomyosarcoma with isolated lung metastases: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Pediatric Blood & Cancer(2023)10.1002/pbc.30293

N/A

0DataRank · unranked

11 citations

Leo Y. Luo, Susan M. Hiniker, Daniel S. Rhee, Roshni Dasgupta, Sonja Chen +5 more

PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+ osteosarcoma: A children’s oncology group pediatric early-phase clinical Trial Network study.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.11527

N/A

0DataRank · unranked

11 citations

Katherine A. Janeway, Charles G. Minard, David Hall, Brian D. Crompton, Alexander J. Lazar +8 more

Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.10008

N/A

0DataRank · unranked

5 citations

Kathleen Ludwig, David Hall, Donald A. Barkauskas, Stephan D. Voss, Steven G. DuBois +12 more